🚀 VC round data is live in beta, check it out!
Cardiff Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cardiff Oncology and similar public comparables like Tetratherix, Milestone Pharmaceuticals, Abionyx Pharma, Mayne Pharma Group and more.
Cardiff Oncology Overview
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Founded
2002
HQ
Employees
31
Website
Sectors
Financials (LTM)
EV
$78M
Cardiff Oncology Financials
Cardiff Oncology reported last 12-month revenue of $527K.
In the same LTM period, Cardiff Oncology generated $527K in gross profit and had net loss of ($46M).
Revenue (LTM)
Cardiff Oncology P&L
In the most recent fiscal year, Cardiff Oncology reported revenue of $593K and EBITDA of ($48M).
Cardiff Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $527K | XXX | $593K | XXX | XXX | XXX |
| Gross Profit | $527K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($48M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8104%) | XXX | XXX | XXX |
| EBIT Margin | (9181%) | XXX | (8256%) | XXX | XXX | XXX |
| Net Profit | ($46M) | XXX | ($46M) | XXX | XXX | XXX |
| Net Margin | (8668%) | XXX | (7732%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cardiff Oncology Stock Performance
Cardiff Oncology has current market cap of $135M, and enterprise value of $78M.
Market Cap Evolution
Cardiff Oncology's stock price is $1.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $135M | 0.0% | XXX | XXX | XXX | $-0.67 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCardiff Oncology Valuation Multiples
Cardiff Oncology trades at 147.9x EV/Revenue multiple, and (1.6x) EV/EBITDA.
EV / Revenue (LTM)
Cardiff Oncology Financial Valuation Multiples
As of April 5, 2026, Cardiff Oncology has market cap of $135M and EV of $78M.
Equity research analysts estimate Cardiff Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cardiff Oncology has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $135M | XXX | $135M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | 147.9x | XXX | 131.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/EBIT | (1.6x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 147.9x | XXX | — | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cardiff Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cardiff Oncology Margins & Growth Rates
Cardiff Oncology's revenue in the last 12 month declined by (38%).
Cardiff Oncology's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.6M for the same period.
Cardiff Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (38%) | XXX | (43%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8104%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2726% | XXX | 2399% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6548% | XXX | 5958% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 8356% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cardiff Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Milestone Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Abionyx Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Mayne Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Shield Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cardiff Oncology M&A Activity
Cardiff Oncology acquired XXX companies to date.
Last acquisition by Cardiff Oncology was on XXXXXXXX, XXXXX. Cardiff Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cardiff Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCardiff Oncology Investment Activity
Cardiff Oncology invested in XXX companies to date.
Cardiff Oncology made its latest investment on XXXXXXXX, XXXXX. Cardiff Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cardiff Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cardiff Oncology
| When was Cardiff Oncology founded? | Cardiff Oncology was founded in 2002. |
| Where is Cardiff Oncology headquartered? | Cardiff Oncology is headquartered in United States. |
| How many employees does Cardiff Oncology have? | As of today, Cardiff Oncology has over 31 employees. |
| Who is the CEO of Cardiff Oncology? | Cardiff Oncology's CEO is Mani Mohindru. |
| Is Cardiff Oncology publicly listed? | Yes, Cardiff Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Cardiff Oncology? | Cardiff Oncology trades under CRDF ticker. |
| When did Cardiff Oncology go public? | Cardiff Oncology went public in 1997. |
| Who are competitors of Cardiff Oncology? | Cardiff Oncology main competitors are Tetratherix, Milestone Pharmaceuticals, Abionyx Pharma, Mayne Pharma Group. |
| What is the current market cap of Cardiff Oncology? | Cardiff Oncology's current market cap is $135M. |
| What is the current revenue of Cardiff Oncology? | Cardiff Oncology's last 12 months revenue is $527K. |
| What is the current revenue growth of Cardiff Oncology? | Cardiff Oncology revenue growth (NTM/LTM) is (38%). |
| What is the current EV/Revenue multiple of Cardiff Oncology? | Current revenue multiple of Cardiff Oncology is 147.9x. |
| Is Cardiff Oncology profitable? | No, Cardiff Oncology is not profitable. |
| What is the current net income of Cardiff Oncology? | Cardiff Oncology's last 12 months net income is ($46M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.